Breaking News Bar

Business News and Information

Cyclerion stock cut in half after disappointing sickle cell trial results

The Cambridge biotech has stopped work on its sophomore drug after it exhibited a lackluster effect in a 70-person study.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
bottom clear